Skip to main content




CanSinoBIO says no serious blood clots from its COVID-19 vaccine

CanSinoBIO says no serious blood clots from its COVID-19 vaccine

FILE PHOTO: A logo of China's vaccine specialist CanSino Biologics Inc is pictured on the company's headquarters in Tianjin, following an outbreak of the coronavirus disease (COVID-19), China August 17, 2020. REUTERS/Thomas Peter

China's CanSino Biologics Inc said on Wednesday (Apr 14) that no serious blood clot cases had been reported in people inoculated with its single-dose COVID-19 vaccine.

US federal health agencies recommended on Tuesday that use of a similar one-shot vaccine from Johnson & Johnson be paused after six women developed rare blood clots.

CanSinoBIO's shares fell as much as 13.7 per cent and 18.4 per cent in Shanghai and Hong Kong respectively. They pared losses to close down 6.3 per cent and 7.7 per cent each after the company issued a statement in which it said: "No blood clot related serious adverse events have been reported in around one million vaccinations of Ad5-nCoV."

CanSinoBIO's Ad5-nCoV vaccine is approved in China, Hungary, Chile, Mexico and Pakistan.

European regulators this month said they had found a possible link between AstraZeneca Plc's vaccine and a similar rare blood clotting problem.

READ: In world first, Denmark ditches AstraZeneca's COVID-19 shot

Several countries have since limited the AstraZeneca vaccine's use to certain age groups, while the European Medicines Agency (EMA) said the benefits outweigh the risks.

Experts said clotting risks for both vaccines remain extremely low and they are highly effective in providing protection against COVID-19, amid concern that reports of the rare side effects could deter people from getting their shots.

READ: US CDC to weigh rare clot risk with Johnson & Johnson's COVID-19 vaccine as use is paused

"There are other vaccines in clinical use where rare side effects are reported – rotavirus, measles, yellow fever. Yet the vaccines save hundreds of thousands of lives," said Jerome Kim, director general of the International Vaccine Institute.

"We are looking at rare events ... Countries need to assess the risk of vaccination against the known risk of not vaccinating."

COVID-19 vaccines from J&J, AstraZeneca, CanSinoBIO and Russia's Gamaleya Institute use various adenoviruses as a vector to deliver DNA instructions for human cells to produce part of the coronavirus that can spur the immune system to recognise SARS-CoV-2.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters/ta


Also worth reading